Singapore markets close in 4 hours 35 minutes
Straits Times Index
3,301.49 +8.80 (+0.27%) Nikkei
38,260.41 -13.64 (-0.04%) Hang Seng
18,155.28 +392.25 (+2.21%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,458.09 -2,758.84 (-4.58%) CMC Crypto 200
1,261.27 -77.79 (-5.81%)
ABT Jan 2025 105.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:54AM EDT. Market open.
| Previous close | 5.90 |
| Open | 5.90 |
| Bid | 5.85 |
| Ask | 6.00 |
| Strike | 105.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.90 - 5.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.75k |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.